Zimberelimab + Domvanalimab
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatobiliary Cancer
Conditions
Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
Trial Timeline
Jun 1, 2023 → Jun 1, 2027
NCT ID
NCT05724563About Zimberelimab + Domvanalimab
Zimberelimab + Domvanalimab is a phase 2 stage product being developed by Arcus Biosciences for Hepatobiliary Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05724563. Target conditions include Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05724563 | Phase 2 | Active |
| NCT05130177 | Phase 2 | Recruiting |
Competing Products
4 competing products in Hepatobiliary Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| Semaglutide + Placebo | Novo Nordisk | Phase 2 | 51 |
| Semaglutide + Placebo | Novo Nordisk | Phase 1 | 32 |
| Phosphatidylcholine | Sanofi | Phase 3 | 76 |
Other Products from Arcus Biosciences
Casdatifan + Cabozantinib + PlaceboPhase 3
72
Quemliclustat + Placebo + Nab-paclitaxel + GemcitabinePhase 3
72
Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 2
47
Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122)Phase 2
47
Zimberelimab + DomvanalimabPhase 2
47